by jtcir-auto | Mar 2, 2022 | Press Releases
– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism – TORONTO, ONTARIO, March 02, 2022 (GLOBE...
by jtcir-auto | Mar 2, 2022 | Press Releases
– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism – TORONTO, ONTARIO, March 02, 2022 (GLOBE...
by jtcir-auto | Feb 7, 2022 | Press Releases
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Feb 7, 2022 | Press Releases
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Jan 26, 2022 | Press Releases
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Jan 26, 2022 | Press Releases
– Company advancing diversified portfolio focused on areas of significant unmet medical need- Supported by solid financial position with cash to fund operations beyond 2023 TORONTO, ONTARIO, Jan. 26, 2022 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ:...